RTTNews | Nov 17, 2021 08:25AM EST

08:25 Wednesday, November 17, 2021 (RTTNews.com) - Moderna Inc. (MRNA) said Wednesday that it has submitted for authorization with Health Canada for the evaluation of a 50 g two-dose series of SPIKEVAX (elasomeran mRNA vaccine) in children ages 6 to 11 years.

The company noted that the phase 2/3 "KidCOVE" study of SPIKEVAX in pediatric population ages 6 months to under 12 years is ongoing. Moderna recently shared new data from the KidCOVE study in children ages 6 years to 11 years. Vaccine efficacy of 100% using the Phase 3 COVE study primary case definition for COVID-19 was observed two weeks after the first dose of SPIKEVAX at the 50 g dose level.

In September 16, 2021, Health Canada approved the New Drug Submission (NDS-CV) for SPIKEVAX for active immunization to prevent COVID-19 in individuals 12 years of age and older.

On November 12, 2021 Health Canada authorized the use of a 50 g booster dose for individuals aged 18 and older administered at least six months after completion of the primary series.

Read the original article on RTTNews ( https://www.rttnews.com/3243125/moderna-files-for-authorization-of-covid-19-vaccine-in-canada-to-include-children-ages-6-11-yrs.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved